310 related articles for article (PubMed ID: 32391636)
1. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
[TBL] [Abstract][Full Text] [Related]
2. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Li B; Li H; Bai Y; Kirschner-Schwabe R; Yang JJ; Chen Y; Lu G; Tzoneva G; Ma X; Wu T; Li W; Lu H; Ding L; Liang H; Huang X; Yang M; Jin L; Kang H; Chen S; Du A; Shen S; Ding J; Chen H; Chen J; von Stackelberg A; Gu L; Zhang J; Ferrando A; Tang J; Wang S; Zhou BB
Nat Med; 2015 Jun; 21(6):563-71. PubMed ID: 25962120
[TBL] [Abstract][Full Text] [Related]
3. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine Resistance in Childhood ALL Is Mediated by PRPS1 Mutations.
Cancer Discov; 2015 Jul; 5(7):693. PubMed ID: 25998402
[TBL] [Abstract][Full Text] [Related]
6. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
7. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.
Gutiérrez MI; Bhatia K; Cherney B; Capello D; Gaidano G; Magrath I
Ann Oncol; 1997 Oct; 8(10):987-94. PubMed ID: 9402172
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
11. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
[TBL] [Abstract][Full Text] [Related]
12. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
13. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
[TBL] [Abstract][Full Text] [Related]
14. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
[TBL] [Abstract][Full Text] [Related]
15. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
[TBL] [Abstract][Full Text] [Related]
16. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
17. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the management of Burkitt's lymphoma.
Levine AM
Clin Lymphoma; 2002 Dec; 3 Suppl 1():S19-25. PubMed ID: 12521385
[TBL] [Abstract][Full Text] [Related]
19. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
20. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.
Cunningham JT; Moreno MV; Lodi A; Ronen SM; Ruggero D
Cell; 2014 May; 157(5):1088-103. PubMed ID: 24855946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]